Loading...
•
Sep 30, 2020
Altimmune Q3 2020 Earnings Report
Altimmune's pipeline matured, and the company progressed five novel investigational candidates into clinical development.
Key Takeaways
Altimmune reported financial results for the third quarter ended September 30, 2020, with a revenue of $2.9 million and a net loss of $17.8 million, or $0.54 net loss per share. The company had cash, cash equivalents, and short-term investments of $206.8 million at the end of the quarter.
Announced positive preclinical results for AdCOVID
Initiated a Phase 1/2 clinical trial of T-COVID; program funded by $4.7 million award from the Department of Defense
Received regulatory clearance to commence a Phase 1 clinical trial of ALT-801 in Australia; Phase 1 trial expected to begin Q4 2020
Secured approximately $200 million in gross proceeds to advance pipeline candidates
Forward Guidance
Altimmune provided forward-looking statements regarding the impact of COVID-19 on business operations, clinical trials and results of operations, the timing of key milestones for clinical assets, and the prospects for regulatory approval.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...